Carl read the papersWhat it actually is
Bronchogen is a synthetic tetrapeptide — Ala-Glu-Asp-Leu — from the class of short peptide bioregulators developed at the St Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson.
The bioregulator premise is that very short peptides derived from a specific tissue can enter cells, reach DNA and influence gene expression in that tissue selectively. Bronchogen is the respiratory member of the family — the lung equivalent of Epithalon's pineal focus.
How it’s thought to work
- Tissue-selective signalling — The bioregulator premise — short peptides derived from a tissue acting preferentially on that tissue.
- Gene expression — Proposed to interact with DNA and modulate transcription in bronchial epithelium.
- Mucociliary clearance — Reported to restore the ciliated cells that clear mucus, in rat studies.
- Immune modulation — Reported effects on secretory IgA production and downregulation of pro-inflammatory cytokines in the respiratory tract.
What the research says
This is where honesty matters. The Khavinson group has published on bioregulators for decades, including rat studies in a COPD model and claims from the same group that it helps people with COPD and chronic bronchitis. The difficulty is that the great majority of it comes from the institute that developed the compounds, much of it in Russian-language journals, with very little independent replication in Western literature. That is not evidence of nothing — but it is a materially different situation from a compound with multi-centre trials behind it.
- Khavinson-family tetrapeptide directed at bronchial and respiratory epithelium.
- Reported effects on ciliated cells, secretory IgA and inflammatory cytokines, in rat studies.
- The developers say it helps in COPD and chronic bronchitis, but the indexed studies are cell and rat work. We found no published human trial.
- Almost all published work originates from the developing institute; independent replication is scarce.
Watch: Bronchogen explained
Video by Peptide Insights on YouTube. Not affiliated with Peptide Carl and not an endorsement — included because a second explanation of the same mechanism is often what makes it click.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Oral | 10–20 mg per day — the bioregulators are unusual in that oral routes are commonly described |
| Subcutaneous | 1–2 mg per day, typically morning, into the abdomen |
| Conservative start | Lower starting doses around 500 mcg daily are reported by people easing in |
| Cycle | 10–20 days, then stop — these are pulsed rather than run continuously |
| Repeat | Every 3–6 months, or seasonally — commonly timed ahead of cold and allergy season |
| Community tip | The cycling is the defining feature of this family. They are described as short courses repeated a few times a year, not daily maintenance — running them continuously is not how the protocols were designed. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Seasonal respiratory course | 10–20 day cycle, repeated every 3–6 months |
| Ahead of cold or allergy season | the most commonly described timing |
| As part of a bioregulator set | alongside Epithalon and the other tissue-specific peptides in the family |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
Two routes are described, which is unusual for a peptide. Oral figures run 10–20 mg daily; subcutaneous runs far lower at 1–2 mg daily, typically in the morning into the abdomen. The defining feature is the cycle: 10–20 days, then stop, repeated every three to six months or timed seasonally ahead of cold and allergy season. This family is pulsed rather than run continuously. Reconstituted, refrigerate and use within the usual window.
Stacks it appears in
- With other bioregulators — The Khavinson compounds are frequently described as a set — Epithalon is the best known of them.
- With Thymosin Alpha-1 — Both appear in immune-focused discussions through quite different mechanisms.
Sources
- Khavinson VKh et al. Peptides tissue-specifically stimulate cell differentiation, Bull Exp Biol Med 2012 (PMID 22808515)
- PubChem: Bronchogen (CID 11690869)
- Monaselidze JR et al. Bronchogen and DNA thermostability, Bull Exp Biol Med 2011 (PMID 21240358)
- Khavinson VKh et al. Peptide regulation of gene expression in bronchial epithelium, Lung 2014 (PMID 25015171)
- Kuzubova NA et al. Peptide therapy and bronchial epithelium in rats with obstructive lung pathology, Bull Exp Biol Med 2015 (PMID 26468022)
- Titova ON et al. Anti-inflammatory and regenerative effect of peptide therapy in obstructive lung pathology model, Ross Fiziol Zh 2017 (PMID 30199201)
- Khavinson V et al. Peptides: prospects for use in COVID-19, Molecules 2020 (PMID 32987757, PMC7583759)
- Vidal.ru (Russian drug reference) search: бронхоген (no Bronchogen entry, 16 Oct 2026)
